MTVA is trading 6.5% down at $1.39 in thin pre-market activity, pulling back after a recent rebound that saw the stock close at $1.49 on June 29.

  • There are no fresh company-specific headlines, filings, or analyst calls to account for the downward move.
  • The current decline appears to be normal volatility in a low-priced biotech name following a period of strength tied to broader market risk-on sentiment.